UPDATE: JPMorgan Downgrades Y-mAbs Therapeutics (YMAB) to Neutral
Tweet Send to a Friend
(Updated - November 16, 2021 3:39 AM EST)
JPMorgan analyst Tessa Romero downgraded Y-mAbs Therapeutics (NASDAQ: YMAB) from Overweight ...
This is a premium only article. To continue reading this and other premium stock market news articles please sign-in or upgrade to StreetInsider.com Premium below (Free Trial) LEARN MORE
JPMorgan analyst Tessa Romero downgraded Y-mAbs Therapeutics (NASDAQ: YMAB) from Overweight ...
This is a premium only article. To continue reading this and other premium stock market news articles please sign-in or upgrade to StreetInsider.com Premium below (Free Trial) LEARN MORE
